Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 12/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 11/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002781 | 0.90 | CSNK1E (0.47) | CSNK1ECSNK1DMAPK14IRAK4MAPK13 | |
| SCHEMBL6004043 | 0.90 | CSNK1E (0.50) | CSNK1ECSNK1DMAPK14 | |
| SCHEMBL6004451 | 0.88 | CSNK1D (0.48) | CSNK1ECSNK1DMAPK14IRAK4MAPK13 | |
| SCHEMBL4719200 | 0.87 | MAPK14 (0.52) | CSNK1ECSNK1DMAPK14MAPK13MAPK12 | |
| Isopropylamine SCHEMBL4791212 | 0.84 | MAPK14 (0.47) | CSNK1ECSNK1DMAPK14MAPK13MAPK12 | |
| SCHEMBL4791217 | 0.81 | MAPK14 (0.46) | CSNK1ECSNK1DMAPK14MAPK13MAPK12 | |
| SCHEMBL4761883 | 0.80 | MAPK14 (0.47) | CSNK1ECSNK1DMAPK14ACKR3 | |
| SCHEMBL6004627 | 0.80 | ACKR3 (0.40) | CSNK1ECSNK1DIRAK4ACKR3PREP | |
| SCHEMBL4721256 | 0.80 | TLR7 (0.46) | CSNK1ECSNK1DMAPK14ACKR3MAPK13 | |
| SCHEMBL6004854 | 0.79 | MAPK14 (0.46) | CSNK1ECSNK1DMAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | CSNK1E 1579/4885CSNK1D 1696/4885MAPK14 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.